Related Experiment Video
Updated: Jan 26, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas
Rita Indirli1,2, Emanuele Ferrante3, Elisa Sala2
1Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Postmenopausal women with microprolactinoma had a lower recurrence rate after stopping cabergoline treatment compared to premenopausal women. However, menopausal status alone does not guarantee long-term remission, necessitating continued follow-up.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Oncology
Background:
- Prolactinomas are pituitary tumors that secrete prolactin.
- The natural course of prolactinomas after menopause is not well understood.
- Cabergoline is a dopamine agonist used to treat prolactinomas.
Purpose of the Study:
- To compare the recurrence rate of microprolactinomas after cabergoline withdrawal in premenopausal versus postmenopausal women.
- To identify factors influencing recurrence risk after treatment cessation.
Main Methods:
- Retrospective study of 62 women with microprolactinoma treated with cabergoline for at least one year.
- Patients were divided into premenopausal (PRE) and postmenopausal (POST) groups based on menopausal status at drug withdrawal.
- Follow-up was conducted for two years post-withdrawal, with recurrence defined by elevated prolactin levels confirmed on two occasions.
Main Results:
- Overall, 39 out of 62 women (63%) relapsed after cabergoline withdrawal.
- The recurrence rate was significantly lower in postmenopausal women (29%) compared to premenopausal women (73%) (p < 0.005).
- Higher prolactin levels before withdrawal were associated with relapse, but multivariate analysis showed no significant correlation between recurrence risk and menopausal status, prolactin levels, treatment duration, or adenoma regression.
Conclusions:
- Postmenopausal status may be associated with a lower risk of prolactinoma recurrence after cabergoline withdrawal, but it cannot reliably predict long-term remission.
- Continued monitoring and follow-up are essential for all women, regardless of menopausal status, after discontinuing cabergoline treatment for microprolactinoma.
Related Concept Videos
Menopause
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Hindsight Biases
Self-Discrepancy Theory

